A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.

Laura Donovan; David Cieremans; Lakshmi Nayak; Yazmin Odia; Fabio Massaiti Iwamoto

doi:10.1200/JCO.2018.36.15_suppl.TPS2073

A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.

Laura Donovan
, David Cieremans
, Lakshmi Nayak
, Yazmin Odia
, Fabio Massaiti Iwamoto

Herbert Wertheim Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	36
DOIs	https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS2073
State	Published - May 20 2018

Disciplines

Medicine and Health Sciences
Pathology
Oncology

Access to Document

10.1200/JCO.2018.36.15_suppl.TPS2073License: Unspecified

Cite this

@article{f0904504abc342069cd60436cb57a166,

title = "A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.",

author = "Laura Donovan and David Cieremans and Lakshmi Nayak and Yazmin Odia and Iwamoto, \{Fabio Massaiti\}",

note = "TPS2073 Background: Gliomas are the most common malignant primary brain tumors in adults. Mutations in Isocitrate dehydrogenonase 1 (IDH1) or IDH2 genes are associated with longer survival. These mutations are found in over 70\% of WHO Grade II and III astrocytomas and are now required for the diagnosis of oligodendroglioma.",

year = "2018",

month = may,

day = "20",

doi = "10.1200/JCO.2018.36.15\_suppl.TPS2073",

language = "American English",

volume = "36",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.

AU - Donovan, Laura

AU - Cieremans, David

AU - Nayak, Lakshmi

AU - Odia, Yazmin

AU - Iwamoto, Fabio Massaiti

N1 - TPS2073 Background: Gliomas are the most common malignant primary brain tumors in adults. Mutations in Isocitrate dehydrogenonase 1 (IDH1) or IDH2 genes are associated with longer survival. These mutations are found in over 70% of WHO Grade II and III astrocytomas and are now required for the diagnosis of oligodendroglioma.

PY - 2018/5/20

Y1 - 2018/5/20

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS2073

U2 - 10.1200/JCO.2018.36.15_suppl.TPS2073

DO - 10.1200/JCO.2018.36.15_suppl.TPS2073

M3 - Article

VL - 36

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.

Disciplines

Access to Document

Other files and links

Cite this